// App-Quantinova.ai

74 : Summary of indirect comparison to evaluate efficacy of baricitinib with targeted synthetic and biologic disease anti-rheumatic drugs in patients with rheumatoid arthritis

Researchers

Presenter

  • Paul Emery

Principal Investigators

  • Jean Dudler

  • Josef Smolen

  • Cristiano Zerbini

  • Gerd Burmester

  • Bruno Fautrel

  • Mart van der Laar

  • Roy Fleischmann

  • Walid Fakhouri

  • Francesco De Leonardis

  • Baojin Zhu

  • Zbigniew Kadziola

  • Inmaculada De La Torre

  • Clementine Perrier

  • Peter C Taylor

Medical Centers

  • Faculty of Medicine and Health, Leeds MSK Biomed/Chapel Allerton Hosp, Leeds, UNITED KINGDOM

  • Department of Rheumatology, HFR Fribourg Hopital cantonal, Fribourg, SWITZERLAND

  • Rheumatology, Medical University Vienna, Vienna, -

  • Department of Rheumatology, Centro de Investigação Clinica, Sao Paulo, BRAZIL

  • Department of Rheumatology and Clinical Immunology, Charite - Universitatsmedizin Berlin, Berlin, Germany

  • Department of Rheumatology, Pierre and Marie Curie University, Paris, FRANCE

  • Department of Rheumatology, Arthritis Center Twente, Enschede, NETHERLANDS

  • Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX

  • Global Health Outcomes, Eli Lilly & Company, Indianapolis, IN

  • Department of Rheumatology, Eli Lilly & Company, Indianapolis, IN

  • Real-World Analytics-Immunology, Eli Lilly & Company, Indianapolis, IN

  • Real-World Analytics-Capabilities and Data Mart, Eli Lilly & Company, Indianapolis, IN

  • Department of Medicine, Eli Lilly & Company, Indianapolis, IN

  • Department of Medicine, Eli Lilly & Company, Indianapolis, IN

  • Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), Botnar Research Centre, University of Oxford, Headington, UNITED KINGDOM

Locations

  • United Kingdom

  • Switzerland

  • Austria

  • Brazil

  • Germany

  • France

  • Netherlands

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Rheumatoid arthritis

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Tocilizumab

  • Baricitinib

  • Tasocitinib

  • Adalimumab

  • BARI

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved